News about "GSK"

US FDA Approves Utebzi for Adult Patients with Complicated UTIs

The US Food and Drug Administration (FDA) has approved GSK’s Utebzi (tebipenem pivoxil) for adults with complicated Urinary Tract Infections (cUTIs), becoming the first and only oral carbapenem antibiotic available. The approval is based on the phase 3 PIVOT-PO trial, which demonstrated non-inferiority to standard intravenous antibiotic treatment.

GSK | 19/06/2026 | By News Bureau

GSK Enters Agreement to Acquire Nuvalent

GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.

GSK | 10/06/2026 | By News Bureau |  203

GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment

GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.

GSK | 29/05/2026 | By News Bureau |  131

GSK Partners with Sino Biopharmaceutical to Accelerate Hepatitis B Therapy Launch in China

GSK and Sino Biopharmaceutical’s CTTQ have partnered to accelerate the launch of bepirovirsen in China, aiming to expand access to a potential first-in-class chronic hepatitis B therapy with functional cure potential.

GSK | 12/05/2026 | By News Bureau

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research

Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.

GSK | 07/05/2026 | By News Bureau |  107

GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million

GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.

GSK | 16/04/2026 | By News Bureau

GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers

GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.

GSK | 14/04/2026 | By News Bureau |  134

NMPA Nod for GSK's Exdensur Boosts Biologics Manufacturing Momentum

GSK plc has received approval from China’s National Medical Products Administration (NMPA) for Exdensur (depemokimab) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in patients aged 12 years and above.

GSK | 31/03/2026 | By Darshana |  108

US FDA Approves GSK's AREXVY for At-Risk Adults Aged 18 to 49 Years

The US FDA has approved GSK’s RSV vaccine, AREXVY, for adults aged 18–49 who are at increased risk of severe RSV infection, expanding protection to an estimated 21 million at-risk individuals in this age group.

GSK | 16/03/2026 | By News Bureau |  120

GSK completes acquisition of RAPT Therapeutics

GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.

GSK | 05/03/2026 | By Akanki |  142